(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease
- PMID: 10406987
- PMCID: PMC1736461
- DOI: 10.1136/jnnp.67.2.189
(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease
Abstract
Objectives: (123)I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy is clinically used to estimate local myocardial sympathetic nerve damage in some forms of heart disease, autonomic nerve disturbance in diabetic neuropathy, and disturbance of the autonomic nervous system in neurodegenerative disease. In the present study, examinations were performed to clarify (1) the proportion of cardiac sympathetic nerve disturbance in Parkinson's disease, (2) the usefulness of (123)I-MIBG myocardial scintigraphy to detect sympathetic nerve disturbances compared with autonomic function tests, (3) cardiac function in patients who have a decreased MIBG uptake in (123)I-MIBG myocardial scintigraphy, (4) the usefulness of (123)I-MIBG myocardial scintigraphy to differentiate Parkinson's disease from the other neurological diseases mimicking it.
Methods: (123)I-MIBG myocardial scintigraphy was performed, together with autonomic function tests and cardiac examinations in 46 patients with Parkinson's disease and 25 patients with vascular parkinsonism, essential tremor, or multiple system atrophy.
Results: In an anterior image study, the average count per pixel in heart to mediastinum (H/M) ratio decreased in 80% of the patients with Parkinson's disease in the early phase and 84% in the late phase. The mean H/M ratio in Parkinson's disease was significantly lower than that in controls and the other diseases. The H/M ratio tended to decrease with the disease progression. In almost half of the patients in Hoehn and Yahr stage I, the H/M ratio was already decreased. The sympathetic skin response in upper and lower limbs, head up tilt test, and coefficient of variation of R-R interval were abnormal in 17%, 31%, 30%, and 17% of the patients, respectively. All the patients with abnormal autonomic functions were in Hoehn and Yahr stage III, IV, or V. Echocardiography showed normal left ventricular function. Twenty four hour Holter electrocardiography detected no serious arrhythmias except for one patient with non-sustained ventricular tachycardia.
Conclusion: (123)I-MIBG myocardial scintigraphy might detect early disturbances of the sympathetic nervous system in Parkinson's disease and might give useful diagnostic information to differentiate vascular parkinsonism, essential tremor, and multiple system atrophy from Parkinson's disease.
Similar articles
-
[Cardiac sympathetic dysfunction in Parkinson's disease--relationship between results of 123I-MIBG scintigraphy and autonomic nervous function evaluated by the Valsalva maneuver].Rinsho Shinkeigaku. 2003 Aug;43(8):465-9. Rinsho Shinkeigaku. 2003. PMID: 14658397 Clinical Trial. Japanese.
-
Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value.J Nucl Med. 1999 Mar;40(3):371-5. J Nucl Med. 1999. PMID: 10086697
-
[Early alteration of adrenergic cardiac function in parkinsonisms with Lewy bodies].Rev Esp Med Nucl. 2005 Mar-Apr;24(2):93-100. doi: 10.1157/13071684. Rev Esp Med Nucl. 2005. PMID: 15745679 Spanish.
-
123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders.Mov Disord. 2009;24 Suppl 2:S732-41. doi: 10.1002/mds.22499. Mov Disord. 2009. PMID: 19877202 Review.
-
123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis.Parkinsonism Relat Disord. 2012 Jun;18(5):494-500. doi: 10.1016/j.parkreldis.2012.01.009. Epub 2012 Feb 8. Parkinsonism Relat Disord. 2012. PMID: 22321865
Cited by
-
On the Utility of MIBG SPECT/CT in Evaluating Cardiac Sympathetic Dysfunction in Lewy Body Diseases.PLoS One. 2016 Apr 7;11(4):e0152746. doi: 10.1371/journal.pone.0152746. eCollection 2016. PLoS One. 2016. PMID: 27055151 Free PMC article. Clinical Trial.
-
Recent progress of imaging agents for Parkinson's disease.Curr Neuropharmacol. 2014 Dec;12(6):551-63. doi: 10.2174/1570159X13666141204221238. Curr Neuropharmacol. 2014. PMID: 25977680 Free PMC article.
-
(123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review.J Mov Disord. 2015 May;8(2):55-66. doi: 10.14802/jmd.15015. Epub 2015 May 31. J Mov Disord. 2015. PMID: 26090077 Free PMC article. Review.
-
Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease.J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):423-6. doi: 10.1136/jnnp.74.4.423. J Neurol Neurosurg Psychiatry. 2003. PMID: 12640054 Free PMC article.
-
Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test.J Neurol. 2011 Mar;258(3):421-6. doi: 10.1007/s00415-010-5769-z. Epub 2010 Oct 12. J Neurol. 2011. PMID: 20938781
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical